Sir,
The great variety of clinical presentations of secondary syphilis deserves a careful and continuous attention as well as the collection and comparison of corresponding dermoscopic findings. 1 On the palm of a 28-year-old man with secondary syphilis, we dermoscopically described a classical Biett's sign of a 3-week-old lesion showing monomorphic dotted and glomerular vessels on a diffuse red to orange background within a circular scaling edge outwardly directed, surrounded by an erythematous halo. 2 Errichetti and Stinco reported the same dermoscopic findings, reporting occasional peripheral telangiectatic vessels. 3 In a young adult woman with 1-month history of diffuse macular rash, Streher and Bonamigo recently described the dermoscopic appearance of hyperkeratotic scalp lesions with an inner circular scaling edge inwardly oriented over a diffuse orangish background with monomorphic dotted vessels, suggesting a peculiar appearance of syphilitic Biett's sign. We would add our further observation on the scalp of a man with secondary syphilis-related macular alopecia. Based on these observations, we can speculate that secondary syphilitic maculo-papular lesions observed under polarized dermoscopy show a background ranging from intense to slight orange according to the body site, the thickness of stratum corneum and dermis and the entity of vascular structures. Thus, lesions on the palm can be orange-reddish in background, whereas lesions on the plantar aspect and scalp may appear orange-yellowish. Similarly, the vascular pattern varies according to the lesion age (more or less inflammatory) and body location (i.e., number of capillaries). The direction of scaling is generally less clearly detectable on older lesions, as fragile scales are more Sir, I read an interesting review article by U Sengupta on elimination of leprosy in India. 1 Of all the issues discussed by the author, the one supporting and even recommending single-dose rifampicin for prevention and controlling leprosy is not supported by scientific facts available currently.
Authors' reply
Single-dose rifampicin treatment is being offered to household contacts of new leprosy patients by the National Leprosy Eradication Program of India in most endemic districts of the country from November 2017. It is a matter of concern because this is not an effective method for preventing multibacillary leprosy and does not protect immediate household contacts for a reasonable period of time. There are serious ethical problems about identifying contacts of patients with leprosy. It is not cost-effective for household contacts, and the possibility with the widespread use of single-dose rifampicin promoting the development of rifampicin resistance genes in M. leprae is real. The author himself has commented on this real possibility.
Taking note of the implementation of single-dose rifampicin by the National Leprosy Control Program of India -me and other colleagues submitted our views in the form of a letter which has been accepted in the PLoS Neglected Tropical Diseases and will be published soon.
2 Given below is the summary of the letter.
The basis of recommendation of single-dose rifampicin is the COLEP trial from Bangladesh. . 4 Significant protection of 56% only lasted 2 years. These findings suggest that single-dose rifampicin treatment is only effective when patients have a low mycobacterial load, hence, the protection is only against the development of paucibacillary leprosy. Because single-dose rifampicin does not significantly reduce the number of patients with multibacillary leprosy, it is unlikely to have an effect on the transmission because these are the patients that need to be diagnosed and treated at the earliest. Moreover, one cannot assume that the index case is the only source of infection to contacts in high endemic settings when there is a possibility of exposure to M. leprae from multiple sources outside the home. We know that a history of contact in the family is present in only one-third of the leprosy patients.
Single-dose rifampicin is being promoted because it is an easier intervention and any intervention that requires more than one dose of the drug/vaccine would be very challenging to administer. More importantly, previous studies on leprosy chemotherapy have found that killing
